Patel K, Vose JM, Nasta SD, Brown JR, Maddocks KJ, Woyach JA, Shah NN, Fakhri B, Tessoulin B, Ma S, Jagadeesh D, Lech-Maranda E, Coombs CC, Patel MR, Rhodes JM, Ujjani C, Hoffmann MS, Cheah CY, Munir T, Lewis D, Scarfò L, Eyre TA, Alencar A, Cohen JB, Zelenetz AD, Tsai DE, Li M, Bian Y, Abada P, Balbas M, Zinzani PL. Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.
, Blood Adv., 10(7): 2026,2441-2451
Landsburg DJ, Musoke N, Gentile C, Brooks TR, Nasta SD, Barta SK, Carter JS, Chong EA, Svoboda J, Schuster SJ, Thomas CJ, Tomasulo EB, Cook MR, Morrissette JJD, Caimi PF, Hill BT. Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma.
, Leukemia, 40(3): 2026,694-697
Ward RE, Dave N, Pai EL, Colbourn R, Banihashemi A, Nasta SD, Babatunde VD. Methotrexate-associated Peripheral Neuropathy on 18 F-FDG PET/CT and MRI Masquerading as Neurolymphomatosis.
, Clin Nucl Med., 51(2): 2026,e144-e146
Jiang C, Hoover T, Baron J, Han X, Li B, Gao Y, Kim M, Hubbeling H, Chong EA, Carter J, Svoboda J, Schuster SJ, Landsburg DJ, Nasta SD, Plastaras J, LaRiviere M. Long Term Results of Proton Therapy in Adult Infradiaphragmatic Lymphoma.
, Int J Part Ther., 19: 2026,101304
Carrie Thompson 1, Marek Trněný 2, Franck Morschhauser 3, Gilles Salles 4, Patrick M Reagan 5, Mark Hertzberg 6, Huilai Zhang 7, Catherine Thieblemont 8, Bei Hu 9, Gustavo Fonseca 10, Won Seog Kim 11, Maurizio Martelli 12, Amitkumar Mehta 13, Avrita Singh 14, Mark Yan 15, Jamie Hirata 14, Matthew Sugidono 14, Calvin Lee 14, Jeff P Sharman 16, Neha Mehta-Shah 17, Christopher R Flowers 18, Hervé Tilly 19, Neil Chua 20, René-Olivier Casasnovas 21, Fiona Miall 22, Tae Min Kim 23, Xavier Cheng-Hong Tsai 24, Sunita Nasta 25, Seung Tae Lee 26, Jonathan W Friedberg 5 PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study
, Blood, 147(3): 2026,254-265
Elghawy O, Sussman JH, Yang AG, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK. Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome.
, JAMA Dermatol., 161(6): 2025 ,e250251
Ward RE, Dave N, Pai EL, Colbourn R, Banihashemi A, Nasta SD, Babatunde VD. Methotrexate-associated Peripheral Neuropathy on 18F-FDG PET/CT and MRI Masquerading as Neurolymphomatosis.
, Clin Nucl Med. : 2025 ,Online ahead of print.
Potluri VS, Zhang S, Schaubel DE, Shaikhouni S, Blumberg EA, Nasta SD, Bloom RD, Cruz-Peralta M, Mehta RB, Lavu NR, Getachew B, Tandukar S, Reese PP, Puttarajappa CM. The Association of Epstein-Barr Virus Donor and Recipient Serostatus With Outcomes After Kidney Transplantation : A Retrospective Cohort Study , Ann Intern Med., 178(2): 2025 ,157-166
Shah NN, Zinzani PL, Wang M, Nasta SD, Lech-Maranda E, Ogawa Y, Fakhri B, Kuss B, Miyashita K, Patel K, Coombs CC, Ma S, Patel MR, Barve MA, Tessoulin B, Stathis A, Ennishi D, Hashimoto D, Kojima K, Zelenetz AD, Cohen JB, Vose JM, Maddocks KJ, Munir T, Sun F, Bian Y, Balbas M, Tsai DE, Abada P, Cheah CY. Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.
, Blood Adv, 9(23): 2025,5954-5964
Stefan Barta, Stephen Schuster, Jakub Svoboda, Jordan Carter, Elise Chong, Daniel Landsburg, Sunita Nasta, Ruchi Patel, Joseph Fraietta, Colin Thomas, Aditya Nimmagadda, Lavanya Peddada, Adam Snook, Nicholas Siciliano, Marco Ruella, Rosemary Mazanet CD5-deleted chimeric antigen receptor cells (Senza5 CART5) to enhance immunotherapy against T-cell non-Hodgkin lymphoma: A first-in-human phase I clinical trial (NCT06420089 , American Society of Clinical Oncology Annual Meeting, Chicago, IL. : 2025
